Role of WNT signaling morphogenic proteins (sclerostin and β-catenin) in adipogenesis

Cover Page

Cite item

Abstract

Adipogenesis relies on complex and multi-faceted mechanism, as it is influenced by multiple cues, including the components from the WNT signaling pathway. The search for possible markers of developing metabolic diseases associated with obesity accounted for an interest to study the morphogenic proteins sclerostin and β-catenin. The aim of the study was to evaluate activity of the WNT signaling pathway in obese patients by measuring level of serum sclerostin and β-catenin proteins. Materials and Methods. There were enrolled 32 patients with metabolic syndrome featured with progressive forms of obesity (class I-III) lacking diabetes mellitus. Concentration of serum sclerostin and β-catenin was measured by using enzyme-linked immunosorbent assay. Data were presented as absolute and relative (%) number of patients; arithmetic mean; medians, 1 and 3 quartiles – Ме (Q0.25-Q0.75). In obese patients, serum sclerostin level (260 (230-308.75) pg/ml) was increased by 13.5% compared with healthy individuals (225 (220-230) pg/ml, (p < 0.001)); concentration of serum sclerostin tended to increase depending on obesity class, most in parallel with decreased β-catenin level, being in agreement with previous studies that might be considered as a prognostic criterion for assessing course of pathological process in obesity.

About the authors

A. S. Kulakova

Bryansk Regional Hospital No. 1

Author for correspondence.
Email: Kulakovaas@mail.ru

Kulakova Anastasiia S. - Gastroenterologist

41033, Bryansk, Stanke Dimitrov ave., 86

Phone: 7 (980) 310-12-33

Russian Federation

I. A. Snimshchikova

I. Turgenev Oryol State University

Email: fake@neicon.ru

PhD, MD (Medicine), Professor, Head, Department of Immunology and Specialized Clinical Disciplines, Director of Medical Institute

Oryol

Russian Federation

M. O. Plotnikova

I. Turgenev Oryol State University

Email: fake@neicon.ru

Senior Lecturer, Department of Immunology and Specialized Clinical Disciplines

Oryol

Russian Federation

References

  1. Amrein K., Amrein S., Drexler C., Dimai H. P., Dobnig H., Pfeifer K., Tomaschitz A., Pieber T.R., Astrid Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J. Clin. Endocrinol. Metab., 2012, Vol. 97, no. 1, pp. 148-154.
  2. Bodine P.V., Stauffer B., Ponce-de-Leon H., Bhat R.A. A small molecule inhibitor of the WNT antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone, 2009, Vol. 44, no. 6, pp. 1063-1068.
  3. Burgers T.A., Williams B.O. Regulation of WNT/β-catenin signaling within and from osteocytes. Bone, 2013, Vol. 54, no. 2, pp. 244-249.
  4. Chen D., Xie R., Shu B., Landay A.L. Wei C. WNT signaling in bone, kidney, intestine, and adipose tissue and inter-organ interaction in aging. Ann. N. Y. Acad. Sci., 2019, Vol. 1442, no. 1, pp. 48-60.
  5. Christodoulides C., Lagathu C., Sethi J.K., Vidal-Puig A. Adipogenesis and WNT signaling. Trends Endocrinol. Metab., 2009, Vol. 20, no. 1, pp. 16-24.
  6. Kim S.P., Frey J.L., Li Z., Kushwaha P., Zoch M.L., Tomlinson R.E., Da H., Aja S.M., Noh H.L., Kim J.K., Hussain M., Thorek D.L.J., Wolfgang M.J., Riddle R. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc. Natl. Acad. Sci. USA, 2017, Vol. 114, no. 52, pp. E11238-E11247.
  7. Klangjareonchai T., Nimitphong H., Saetung S., Bhirommuang N., Samittarucksa R., Sudatip R., Ongphiphadhanakul B. Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int. J. Endocrinol., 2014, Vol. 2014, 261545. doi: 10.1155/2014/261545.
  8. Krause C., Korchynskyi O., Rooij K., Weidauer S.E., Gorter D.J. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and WNT signaling pathways. Biol. Chem., 2010, Vol. 285, no. 53, pp. 41614-41626.
  9. Malinauskas T., Aricescu R., Lu W., Siebold C., Jones E.Y. Modular mechanism of WNT signaling inhibition by WNT inhibitory factor 1. Nat. Struct. Mol. Biol., 2011, Vol. 18, no. 8, pp. 886-893.
  10. Medeiros M.C. Rocha N., Bandeira E., Dantas I., Serum sclerostin, body composition, and sarcopenia in hemodialysis patients with diabetes. Int. J. Nephrol., 2020, Vol. 2020, 4596920. doi: 10.1155/2020/4596920.
  11. Ng L.F., Kaur P., Bunnag N., Suresh J., Sung I.C.H., Tan Q.H., Gruber J., Tolwinski N.S. WNT signaling in disease. Cells, 2019, Vol. 8, no. 8, pp. 826-857.
  12. Saito-Diaz K. Chen T.W., Wang X., Thorne C.A., Wallace H.A. The way WNT works: components and mechanism. Growth Factors, 2013, Vol. 31, no. 1, pp. 1-31.
  13. Urano T., Shiraki M., Ouchi Y., Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease: related markers in Japanese postmenopausal women. J. Clin. Endocrinol. Metab., 2012, Vol. 97, pp. 1473-1477.
  14. Witte F., Dokas J., Neuendorf F., Mundlos S., Stricker S. Comprehensive expression analysis of all WNT genes and their major secreted antagonists during mouse limb development and cartilage differentiation. Gene Expr. Patterns, 2009, Vol. 9, no. 4, pp. 215-223.

Copyright (c) 2020 Kulakova A.S., Snimshchikova I.A., Plotnikova M.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies